person · Reporting owner

Machado Patrick

Disclosed activity across 18 companies

Tapewire entity: 32934
SEC CIK: 0001311210

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
ALUMIS INC.ALMS · Entity 4816	Director	June 30, 2026	July 02, 2026
Arcus Biosciences, Inc.RCUS · Entity 4104	Director	June 11, 2026	June 12, 2026
CHIMERIX INCCMRX · Entity 80651	Director	June 09, 2023	June 12, 2023
ROCKET PHARMACEUTICALS, INC.ITEK · Entity 5627	Director	June 20, 2017	June 21, 2017
Roivant Sciences Ltd.ROIV · Entity 3185	Director	October 01, 2021	October 01, 2021
SCYNEXIS INCSCYX · Entity 7194	Director	January 02, 2019	January 04, 2019
Turnstone Biologics Corp.TSBX · Entity 76646	Director	July 20, 2023	July 21, 2023
Xenon Pharmaceuticals Inc.XENE · Entity 2602	Director	June 01, 2026	June 04, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ALUMIS INC.

Report date June 30, 2026 · Filed July 02, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	3,553	Reported balance After 2026-06-30 transaction · row 1 1 source row Row 1 · 2026-06-30 · Grant · Acquired 3,553 · Balance 3,553 F1: Represents shares of common stock issuable upon settlement of a restricted stock unit ("RSU") grant. The shares underlying this RSU vest on the first anniversary of the date of grant, provided that the shares will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2024 Equity Incentive Plan (the "Plan")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan), subject to the Reporting Person's Continuous Service (as defined in the Plan) through such date.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.14 · Expires 2036-06-29	Direct	15,528	Reported balance After 2026-06-30 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-06-30 · Grant · Acquired 15,528 · Balance 15,528 F3: The shares underlying this option vest on the first anniversary of the date of grant, provided that the shares will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the Plan) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan), subject to the Reporting Person's Continuous Service (as defined in the Plan) through such date.
Common StockSEC Table I · non-derivative	IndirectBy Trust	7,064	Reported balance Holding disclosure · report date 2026-06-30 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 7,064 F2: Shares held directly by Patrick Machado Revocable Trust, Patrick Machado, TEE, for which the Reporting Person serves as trustee.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares of common stock issuable upon settlement of a restricted stock unit ("RSU") grant. The shares underlying this RSU vest on the first anniversary of the date of grant, provided that the shares will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2024 Equity Incentive Plan (the "Plan")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan), subject to the Reporting Person's Continuous Service (as defined in the Plan) through such date.

F2: Shares held directly by Patrick Machado Revocable Trust, Patrick Machado, TEE, for which the Reporting Person serves as trustee.

F3: The shares underlying this option vest on the first anniversary of the date of grant, provided that the shares will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the Plan) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan), subject to the Reporting Person's Continuous Service (as defined in the Plan) through such date.

Arcus Biosciences, Inc.

Report date June 11, 2026 · Filed June 12, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	44,300	Reported balance After 2026-06-11 transaction · row 1 1 source row Row 1 · 2026-06-11 · Grant · Acquired 5,700 · Balance 44,300 F1: Represents the grant of restricted stock units that vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.30 · Expires 2036-06-10	Direct	16,900	Reported balance After 2026-06-11 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-06-11 · Grant · Acquired 16,900 · Balance 16,900 F2: The option will vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The option will become fully vested and exercisable in the event the Company is subject to a change in control.

Filing footnotes · ownership attribution and instrument terms

F1: Represents the grant of restricted stock units that vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control.

F2: The option will vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The option will become fully vested and exercisable in the event the Company is subject to a change in control.

CHIMERIX INC

Report date June 09, 2023 · Filed June 12, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.39 · Expires 2033-06-08	Direct	60,000	Reported balance After 2023-06-09 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2023-06-09 · Grant · Acquired 60,000 · Balance 60,000 F1: The shares subject to the option vest in a series of 12 equal monthly installments from the date of grant; provided, however, that the option shall become fully vested on the date that is the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the Company's 2024 annual stockholder meeting.

Filing footnotes · ownership attribution and instrument terms

F1: The shares subject to the option vest in a series of 12 equal monthly installments from the date of grant; provided, however, that the option shall become fully vested on the date that is the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the Company's 2024 annual stockholder meeting.

ROCKET PHARMACEUTICALS, INC.

Report date June 20, 2017 · Filed June 21, 2017

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.80 · Expires 2027-06-19	Direct	45,000	Reported balance After 2017-06-20 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2017-06-20 · Grant · Acquired 45,000 · Balance 45,000 F1: This stock option award was issued pursuant to Inotek Pharmaceuticals Corporation's 2014 Stock Option and Incentive Plan. The option shall vest in equal quarterly installments at the end of each quarter following June 20, 2017, subject to continued service through such dates.

Filing footnotes · ownership attribution and instrument terms

F1: This stock option award was issued pursuant to Inotek Pharmaceuticals Corporation's 2014 Stock Option and Incentive Plan. The option shall vest in equal quarterly installments at the end of each quarter following June 20, 2017, subject to continued service through such dates.

Roivant Sciences Ltd.

Report date October 01, 2021 · Filed October 01, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.19 · Expires 2026-10-19	Direct	Not disclosed	Reported balance Holding disclosure · report date 2021-10-01 · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · Balance Not disclosed F1: Award of stock options to purchase Common Shares that is fully vested.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.43 · Expires 2027-12-19	Direct	Not disclosed	Reported balance Holding disclosure · report date 2021-10-01 · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · Balance Not disclosed F1: Award of stock options to purchase Common Shares that is fully vested.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.19 · Expires 2029-01-21	Direct	Not disclosed	Reported balance Holding disclosure · report date 2021-10-01 · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · Balance Not disclosed F2: Award of stock options to purchase Common Shares with a vesting commencement date of November 30, 2018. F5: Awards of stock options to purchase Common Shares vest and become exercisable (i) 33% on the first anniversary of the applicable vesting commencement date and (ii) in 24 equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.68 · Expires 2030-01-19	Direct	Not disclosed	Reported balance Holding disclosure · report date 2021-10-01 · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · Balance Not disclosed F3: Award of stock options to purchase Common Shares with a vesting commencement date of November 30, 2019. F5: Awards of stock options to purchase Common Shares vest and become exercisable (i) 33% on the first anniversary of the applicable vesting commencement date and (ii) in 24 equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.00 · Expires 2031-05-01	Direct	Not disclosed	Reported balance Holding disclosure · report date 2021-10-01 · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · Balance Not disclosed F4: Award of stock options to purchase Common Shares with a vesting commencement date of December 27, 2019. F5: Awards of stock options to purchase Common Shares vest and become exercisable (i) 33% on the first anniversary of the applicable vesting commencement date and (ii) in 24 equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: Award of stock options to purchase Common Shares that is fully vested.

F2: Award of stock options to purchase Common Shares with a vesting commencement date of November 30, 2018.

F3: Award of stock options to purchase Common Shares with a vesting commencement date of November 30, 2019.

F4: Award of stock options to purchase Common Shares with a vesting commencement date of December 27, 2019.

F5: Awards of stock options to purchase Common Shares vest and become exercisable (i) 33% on the first anniversary of the applicable vesting commencement date and (ii) in 24 equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date.

SCYNEXIS INC

Report date January 02, 2019 · Filed January 04, 2019

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.54 · Expires 2029-01-01	Direct	22,500	Reported balance After 2019-01-02 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2019-01-02 · Grant · Acquired 22,500 · Balance 22,500 F1: One-hundred percent (100%) of the shares subject to the option vest on the first anniversary of the date of grant, provided that the non-employee director is providing continuous services on the applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: One-hundred percent (100%) of the shares subject to the option vest on the first anniversary of the date of grant, provided that the non-employee director is providing continuous services on the applicable vesting date.

Turnstone Biologics Corp.

Report date July 20, 2023 · Filed July 21, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.87 · Expires 2028-08-06	Direct	Not disclosed	Reported balance Holding disclosure · report date 2023-07-20 · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · Balance Not disclosed F1: Immediately exercisable.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.30 · Expires 2031-02-21	Direct	Not disclosed	Reported balance Holding disclosure · report date 2023-07-20 · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · Balance Not disclosed F2: This option vested or shall vest in forty-eight (48) equal monthly installments commencing on March 22, 2021, subject to the Reporting Person's continuous service through each such vesting date.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.94 · Expires 2032-01-19	Direct	Not disclosed	Reported balance Holding disclosure · report date 2023-07-20 · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · Balance Not disclosed F3: One fourth (1/4th) of the shares subject to the option award vested on January 20, 2023, and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: Immediately exercisable.

F2: This option vested or shall vest in forty-eight (48) equal monthly installments commencing on March 22, 2021, subject to the Reporting Person's continuous service through each such vesting date.

F3: One fourth (1/4th) of the shares subject to the option award vested on January 20, 2023, and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.

Xenon Pharmaceuticals Inc.

Report date June 01, 2026 · Filed June 04, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common SharesSEC Table I · non-derivative	Direct	2,645	Reported balance After 2026-06-01 transaction · row 1 1 source row Row 1 · 2026-06-01 · Exercise / conversion · Acquired 2,645 · Balance 2,645 F1: Represents Common Shares earned and vested under a restricted share unit ("RSU") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders.
Restricted Share UnitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2026-06-01 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-06-01 · Exercise / conversion · Disposed 2,645 · Balance 0 F1: Represents Common Shares earned and vested under a restricted share unit ("RSU") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders.
Restricted Share UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	1,593	Reported balance After 2026-06-03 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-06-03 · Grant · Acquired 1,593 · Balance 1,593 F3: Each RSU represents a contingent right to receive one Common Share vesting 100% on the earlier of (i) June 1, 2027 or (ii) the day before the date of the issuer's 2027 annual meeting of shareholders.
Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $53.46 · Expires 2036-06-02	Direct	10,507	Reported balance After 2026-06-03 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-06-03 · Grant · Acquired 10,507 · Balance 10,507 F2: Vesting 100% on the earlier of (i) June 1, 2027 or (ii) the day before the date of the issuer's 2027 annual meeting of shareholders.

Filing footnotes · ownership attribution and instrument terms

F1: Represents Common Shares earned and vested under a restricted share unit ("RSU") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders.

F2: Vesting 100% on the earlier of (i) June 1, 2027 or (ii) the day before the date of the issuer's 2027 annual meeting of shareholders.

F3: Each RSU represents a contingent right to receive one Common Share vesting 100% on the earlier of (i) June 1, 2027 or (ii) the day before the date of the issuer's 2027 annual meeting of shareholders.

Past disclosures · reporting ended (10)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

ACELYRIN, Inc.

Report date May 21, 2025 · Filed May 23, 2025

Section 16 reporting ended · disclosed 2025-05-23. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee footnote	Reported balance After 2025-05-21 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2025-05-21 · Disposition to issuer · Disposed 14,675 · Balance 0 F1: On February 6, 2025, ACELYRIN, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (as amended on April 20, 2025, the "Merger Agreement") with Alumis, Inc., a Delaware corporation ("Parent"), and Arrow Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of common stock, par value $0.00001 per share, of the Company issued and outstanding was converted into the right to receive 0.4814 (the "Exchange Ratio") shares of voting common stock of Parent, par value $0.0001 per share ("Parent Common Stock"), and cash in lieu of any fractional shares. F2: Shares held directly by Patrick Machado Revocable Trust, Patrick Machado, TEE, for which the Reporting Person serves as trustee.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.46 · Expires 2034-06-06	Direct	Reported balance After 2025-05-21 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2025-05-21 · Disposition to issuer · Disposed 92,158 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per share exercise price of $18.00 or less was assumed by Parent and converted into an option to purchase a number of shares of Parent Common Stock equal to (i) the number of shares subject to the option immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, which stock option shall have an exercise price equal to (i) the per share exercise price for shares subject to the corresponding Company stock option immediately prior to the Effective Time, divided by (ii) the Exchange Ratio, rounded up to the nearest whole cent. F3: All of the shares subject to the option vest on the earlier of (i) June 7, 2025, or (ii) the day immediately preceding the next annual meeting of stockholders following the grant date of the option, subject to the Reporting Person's continued service as a director through the vesting date.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.00 · Expires 2033-05-03	Direct	Reported balance After 2025-05-21 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2025-05-21 · Disposition to issuer · Disposed 23,243 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per share exercise price of $18.00 or less was assumed by Parent and converted into an option to purchase a number of shares of Parent Common Stock equal to (i) the number of shares subject to the option immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, which stock option shall have an exercise price equal to (i) the per share exercise price for shares subject to the corresponding Company stock option immediately prior to the Effective Time, divided by (ii) the Exchange Ratio, rounded up to the nearest whole cent. F5: 1/36 of the shares subject to the option vested on June 4, 2023, and 1/36 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.88 · Expires 2032-11-20	Direct	Reported balance After 2025-05-21 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2025-05-21 · Disposition to issuer · Disposed 28,675 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per share exercise price of $18.00 or less was assumed by Parent and converted into an option to purchase a number of shares of Parent Common Stock equal to (i) the number of shares subject to the option immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, which stock option shall have an exercise price equal to (i) the per share exercise price for shares subject to the corresponding Company stock option immediately prior to the Effective Time, divided by (ii) the Exchange Ratio, rounded up to the nearest whole cent. F6: 1/48 of the shares subject to the option vested on December 17, 2022 and 1/48 of the shares subject to the option vests in equal monthly installments thereafter, subject to the Reporting Person's continued service.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.88 · Expires 2032-11-20	Direct	Reported balance After 2025-05-21 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2025-05-21 · Disposition to issuer · Disposed 86,206 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per share exercise price of $18.00 or less was assumed by Parent and converted into an option to purchase a number of shares of Parent Common Stock equal to (i) the number of shares subject to the option immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, which stock option shall have an exercise price equal to (i) the per share exercise price for shares subject to the corresponding Company stock option immediately prior to the Effective Time, divided by (ii) the Exchange Ratio, rounded up to the nearest whole cent. F7: 1/48 of the shares subject to the option vested on November 1, 2022 and 1/48 of the shares subject to the option vests in equal monthly installments thereafter, subject to the Reporting Person's continued service.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.77 · Expires 2031-07-25	Direct	Reported balance After 2025-05-21 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2025-05-21 · Disposition to issuer · Disposed 40,567 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per share exercise price of $18.00 or less was assumed by Parent and converted into an option to purchase a number of shares of Parent Common Stock equal to (i) the number of shares subject to the option immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, which stock option shall have an exercise price equal to (i) the per share exercise price for shares subject to the corresponding Company stock option immediately prior to the Effective Time, divided by (ii) the Exchange Ratio, rounded up to the nearest whole cent. F8: 1/48 of the shares subject to the option vested on May 19, 2021 and 1/48 of the shares subject to the option vests in equal monthly installments thereafter, subject to the Reporting Person's continued service.

Filing footnotes · ownership attribution and instrument terms

F1: On February 6, 2025, ACELYRIN, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (as amended on April 20, 2025, the "Merger Agreement") with Alumis, Inc., a Delaware corporation ("Parent"), and Arrow Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of common stock, par value $0.00001 per share, of the Company issued and outstanding was converted into the right to receive 0.4814 (the "Exchange Ratio") shares of voting common stock of Parent, par value $0.0001 per share ("Parent Common Stock"), and cash in lieu of any fractional shares.

F2: Shares held directly by Patrick Machado Revocable Trust, Patrick Machado, TEE, for which the Reporting Person serves as trustee.

F3: All of the shares subject to the option vest on the earlier of (i) June 7, 2025, or (ii) the day immediately preceding the next annual meeting of stockholders following the grant date of the option, subject to the Reporting Person's continued service as a director through the vesting date.

F4: Pursuant to the Merger Agreement, at the Effective Time each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per share exercise price of $18.00 or less was assumed by Parent and converted into an option to purchase a number of shares of Parent Common Stock equal to (i) the number of shares subject to the option immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, which stock option shall have an exercise price equal to (i) the per share exercise price for shares subject to the corresponding Company stock option immediately prior to the Effective Time, divided by (ii) the Exchange Ratio, rounded up to the nearest whole cent.

F5: 1/36 of the shares subject to the option vested on June 4, 2023, and 1/36 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service.

F6: 1/48 of the shares subject to the option vested on December 17, 2022 and 1/48 of the shares subject to the option vests in equal monthly installments thereafter, subject to the Reporting Person's continued service.

F7: 1/48 of the shares subject to the option vested on November 1, 2022 and 1/48 of the shares subject to the option vests in equal monthly installments thereafter, subject to the Reporting Person's continued service.

F8: 1/48 of the shares subject to the option vested on May 19, 2021 and 1/48 of the shares subject to the option vests in equal monthly installments thereafter, subject to the Reporting Person's continued service.

Adverum Biotechnologies, Inc.

Report date December 09, 2025 · Filed December 10, 2025

Section 16 reporting ended · disclosed 2025-12-10. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2025-12-09 transaction · row 1 1 source row Row 1 · 2025-12-09 · Other · Disposed 8,818 · Balance 0 F1: In connection with the terms of an Agreement and Plan of Merger, dated as of October 24, 2025 (the "Merger Agreement"), by and among the Issuer, Eli Lilly and Company ("Parent") and Parent's direct wholly owned subsidiary, Flying Tigers Acquisition Corporation ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's Common Stock. In exchange for each share, tendering stockholders received: (i) $3.56 per share in cash, without interest and less any applicable tax withholding (the "Cash Consideration"); plus (ii) one non-tradable contingent value right (each, a "CVR"), which represents the contractual right to receive up to two contingent cash payments of up to an aggregate of $8.91 per CVR, net to the stockholder in cash, F2: (continued from footnote 1) without interest and less any applicable tax withholding, upon the achievement of both specified milestones in accordance with the terms and subject to the conditions of a contingent value rights agreement (the "CVR Agreement") with Computershare Inc. and its affiliate, Computershare Trust Company, N.A, as the rights agent. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the "Merger"), effective as of December 9, 2025, with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent (the "Effective Time").
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $64.00	Direct	Reported balance After 2025-12-09 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2025-12-09 · Disposition to issuer · Disposed 1,000 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an "Out-of-the-Money Option"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.50	Direct	Reported balance After 2025-12-09 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2025-12-09 · Disposition to issuer · Disposed 6,476 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an "Out-of-the-Money Option"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.50	Direct	Reported balance After 2025-12-09 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2025-12-09 · Disposition to issuer · Disposed 3,360 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an "Out-of-the-Money Option"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $62.50	Direct	Reported balance After 2025-12-09 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2025-12-09 · Disposition to issuer · Disposed 3,500 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an "Out-of-the-Money Option"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $134.10	Direct	Reported balance After 2025-12-09 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2025-12-09 · Disposition to issuer · Disposed 4,500 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an "Out-of-the-Money Option"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $115.20	Direct	Reported balance After 2025-12-09 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2025-12-09 · Disposition to issuer · Disposed 1,500 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an "Out-of-the-Money Option"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $256.40	Direct	Reported balance After 2025-12-09 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2025-12-09 · Disposition to issuer · Disposed 3,000 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an "Out-of-the-Money Option"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $37.00	Direct	Reported balance After 2025-12-09 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2025-12-09 · Disposition to issuer · Disposed 5,250 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an "Out-of-the-Money Option"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.90	Direct	Reported balance After 2025-12-09 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2025-12-09 · Disposition to issuer · Disposed 5,250 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an "Out-of-the-Money Option"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.60	Direct	Reported balance After 2025-12-09 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2025-12-09 · Disposition to issuer · Disposed 5,250 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an "Out-of-the-Money Option"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.32	Direct	Reported balance After 2025-12-09 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2025-12-09 · Disposition to issuer · Disposed 13,820 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an "Out-of-the-Money Option"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.32	Direct	Reported balance After 2025-12-09 transaction · row 13 Instrument identity requires review; Table II rows are not merged. 1 source row Row 13 · 2025-12-09 · Disposition to issuer · Disposed 13,590 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding stock option granted under a Company Equity Plan having an exercise price less than the Cash Consideration (each such option, a "Cash-Out Stock Option") that was outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, and in exchange for such cancellation, the holder of such Cash-Out Stock Option received (i) an amount in cash, without interest and less any applicable tax withholdings, equal to the product of (a) the excess, if any, of the Cash Consideration over the applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares subject to such Cash-Out Stock Option and (ii) one CVR for each share subject to such Cash-Out Stock Option (without regard to vesting).

Filing footnotes · ownership attribution and instrument terms

F1: In connection with the terms of an Agreement and Plan of Merger, dated as of October 24, 2025 (the "Merger Agreement"), by and among the Issuer, Eli Lilly and Company ("Parent") and Parent's direct wholly owned subsidiary, Flying Tigers Acquisition Corporation ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's Common Stock. In exchange for each share, tendering stockholders received: (i) $3.56 per share in cash, without interest and less any applicable tax withholding (the "Cash Consideration"); plus (ii) one non-tradable contingent value right (each, a "CVR"), which represents the contractual right to receive up to two contingent cash payments of up to an aggregate of $8.91 per CVR, net to the stockholder in cash,

F2: (continued from footnote 1) without interest and less any applicable tax withholding, upon the achievement of both specified milestones in accordance with the terms and subject to the conditions of a contingent value rights agreement (the "CVR Agreement") with Computershare Inc. and its affiliate, Computershare Trust Company, N.A, as the rights agent. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the "Merger"), effective as of December 9, 2025, with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent (the "Effective Time").

F3: Pursuant to the terms of the Merger Agreement, each Company Stock Option that has an exercise price equal to or greater than the Cash Consideration that was outstanding immediately prior to the Effective Time (each such Company Stock Option, an "Out-of-the-Money Option"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time was cancelled for no consideration at the Effective Time.

F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding stock option granted under a Company Equity Plan having an exercise price less than the Cash Consideration (each such option, a "Cash-Out Stock Option") that was outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, and in exchange for such cancellation, the holder of such Cash-Out Stock Option received (i) an amount in cash, without interest and less any applicable tax withholdings, equal to the product of (a) the excess, if any, of the Cash Consideration over the applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares subject to such Cash-Out Stock Option and (ii) one CVR for each share subject to such Cash-Out Stock Option (without regard to vesting).

Arbutus Biopharma Corp

Report date July 10, 2019 · Filed July 16, 2019

Section 16 reporting ended · disclosed 2019-07-16. Current position is not established by this disclosure.

No balance rows disclosed in this filing.

ENDOCYTE INC

Report date December 21, 2018 · Filed December 21, 2018

Section 16 reporting ended · disclosed 2018-12-21. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2018-12-21 transaction · row 1 Sequence does not reconcile; account continuity is unresolved. 1 source row Row 1 · 2018-12-21 · Disposition to issuer · Disposed 1,250 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 17, 2018 (the "Merger Agreement"), by and among Endocyte, Inc. (the "Company"), Novartis AG ("Novartis") and Edinburgh Merger Corporation, a wholly owned subsidiary of Novartis ("Merger Sub"), at the effective time (the "Effective Time") of the merger of Merger Sub with and into the Company, which Effective Time occurred on December 21, 2018, each share of Company common stock was converted into the right to receive an amount in cash equal to $24.00, without interest and less any applicable withholding taxes.
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2018-12-21 transaction · row 2 Sequence does not reconcile; account continuity is unresolved. 1 source row Row 2 · 2018-12-21 · Disposition to issuer · Disposed 2,500 · Balance 0 F2: This restricted stock unit ("RSU") award provided for vesting and settlement 1/3 on the business day before each of the Company's three annual stockholder meetings following February 27, 2018 in the form of one share of Company common stock for each RSU. Pursuant to the Merger Agreement, at the Effective Time, each RSU outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to $24.00, multiplied by the number of shares of Company common stock subject to such RSU, less any applicable withholding taxes.
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2018-12-21 transaction · row 3 Sequence does not reconcile; account continuity is unresolved. 1 source row Row 3 · 2018-12-21 · Disposition to issuer · Disposed 3,300 · Balance 0 F3: This RSU award provided for vesting and settlement 100% on the business day prior to the Company's annual stockholder meeting following May 3, 2018 in the form of one share of Company common stock for each RSU. Pursuant to the Merger Agreement, at the Effective Time, each RSU outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to $24.00, multiplied by the number of shares of Company common stock subject to such RSU, less any applicable withholding taxes.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.20 · Expires 2028-02-27	Direct	Reported balance After 2018-12-21 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2018-12-21 · Disposition to issuer · Disposed 22,500 · Balance 0 F4: This Company stock option was scheduled to vest 1/3 on the business day before each of the Company's three annual stockholder meetings following February 27, 2018. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.81 · Expires 2028-05-03	Direct	Reported balance After 2018-12-21 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2018-12-21 · Disposition to issuer · Disposed 19,500 · Balance 0 F5: This Company stock option was scheduled to vest 100% on the business day prior to the Company's annual stockholder meeting following May 3, 2018. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger, dated as of October 17, 2018 (the "Merger Agreement"), by and among Endocyte, Inc. (the "Company"), Novartis AG ("Novartis") and Edinburgh Merger Corporation, a wholly owned subsidiary of Novartis ("Merger Sub"), at the effective time (the "Effective Time") of the merger of Merger Sub with and into the Company, which Effective Time occurred on December 21, 2018, each share of Company common stock was converted into the right to receive an amount in cash equal to $24.00, without interest and less any applicable withholding taxes.

F2: This restricted stock unit ("RSU") award provided for vesting and settlement 1/3 on the business day before each of the Company's three annual stockholder meetings following February 27, 2018 in the form of one share of Company common stock for each RSU. Pursuant to the Merger Agreement, at the Effective Time, each RSU outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to $24.00, multiplied by the number of shares of Company common stock subject to such RSU, less any applicable withholding taxes.

F3: This RSU award provided for vesting and settlement 100% on the business day prior to the Company's annual stockholder meeting following May 3, 2018 in the form of one share of Company common stock for each RSU. Pursuant to the Merger Agreement, at the Effective Time, each RSU outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to $24.00, multiplied by the number of shares of Company common stock subject to such RSU, less any applicable withholding taxes.

F4: This Company stock option was scheduled to vest 1/3 on the business day before each of the Company's three annual stockholder meetings following February 27, 2018. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes.

F5: This Company stock option was scheduled to vest 100% on the business day prior to the Company's annual stockholder meeting following May 3, 2018. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes.

MEDIVATION, INC.

Report date September 28, 2016 · Filed September 30, 2016

Section 16 reporting ended · disclosed 2016-09-30. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2016-09-28 transaction · row 1 1 source row Row 1 · 2016-09-28 · Other · Disposed 70,792 · Balance 0 F1: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated August 20, 2016, among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Montreal, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Purchaser"), in exchange for a cash consideration of $81.50 per share (without interest) subject to any required withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger"). In connection with the Merger, Purchaser offered to purchase all of the outstanding shares of common stock, par value $0.01 per share of the Issuer, at a price of $81.50 per share, net to the seller in cash (without interest) but subject to any required withholding of taxes, upon the terms and conditions set forth in the offer to purchase dated August 30, 2016, and in the related letter of transmittal. F2: Includes 2,972 unvested shares subject to a restricted stock award.
Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.64 · Expires 2019-12-15	Direct	Reported balance After 2016-09-28 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2016-09-28 · Disposition to issuer · Disposed 264,000 · Balance 0 F3: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger.
Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.37 · Expires 2020-12-15	Direct	Reported balance After 2016-09-28 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2016-09-28 · Disposition to issuer · Disposed 33,336 · Balance 0 F3: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger.
Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.43 · Expires 2022-12-17	Direct	Reported balance After 2016-09-28 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2016-09-28 · Disposition to issuer · Disposed 90,000 · Balance 0 F3: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger.
Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $38.89 · Expires 2024-06-27	Direct	Reported balance After 2016-09-28 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2016-09-28 · Disposition to issuer · Disposed 9,584 · Balance 0 F3: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger.
Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $55.45 · Expires 2025-06-16	Direct	Reported balance After 2016-09-28 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2016-09-28 · Disposition to issuer · Disposed 6,284 · Balance 0 F3: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger.
Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $58.89 · Expires 2026-06-22	Direct	Reported balance After 2016-09-28 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2016-09-28 · Disposition to issuer · Disposed 6,228 · Balance 0 F3: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger.
Stock Appreciation RightsSEC Table II · derivative / convertible security · Conversion / exercise price $12.20 · Expires 2021-12-09	Direct	Reported balance After 2016-09-28 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2016-09-28 · Disposition to issuer · Disposed 222,800 · Balance 0 F4: This stock appreciation right (the "SAR") was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share base price of the SAR.

Filing footnotes · ownership attribution and instrument terms

F1: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated August 20, 2016, among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Montreal, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Purchaser"), in exchange for a cash consideration of $81.50 per share (without interest) subject to any required withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger"). In connection with the Merger, Purchaser offered to purchase all of the outstanding shares of common stock, par value $0.01 per share of the Issuer, at a price of $81.50 per share, net to the seller in cash (without interest) but subject to any required withholding of taxes, upon the terms and conditions set forth in the offer to purchase dated August 30, 2016, and in the related letter of transmittal.

F2: Includes 2,972 unvested shares subject to a restricted stock award.

F3: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger.

F4: This stock appreciation right (the "SAR") was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share base price of the SAR.

Myovant Sciences Ltd.

Report date July 10, 2019 · Filed July 16, 2019

Section 16 reporting ended · disclosed 2019-07-16. Current position is not established by this disclosure.

No balance rows disclosed in this filing.

Principia Biopharma Inc.

Report date September 28, 2020 · Filed September 28, 2020

Section 16 reporting ended · disclosed 2020-09-28. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.77 · Expires 2029-06-10	Direct	Reported balance After 2020-09-28 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2020-09-28 · Disposition to issuer · Disposed 20,475 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of August 16, 2020, by and among Principia Biopharma Inc. (the "Issuer"), Sanofi ("Sanofi") and Kortex Acquisition Corp. ("Purchaser") (the "Merger Agreement"), on September 28, 2020, Purchaser merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Sanofi (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.77 · Expires 2029-06-10	Direct	Reported balance After 2020-09-28 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2020-09-28 · Disposition to issuer · Disposed 10,240 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of August 16, 2020, by and among Principia Biopharma Inc. (the "Issuer"), Sanofi ("Sanofi") and Kortex Acquisition Corp. ("Purchaser") (the "Merger Agreement"), on September 28, 2020, Purchaser merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Sanofi (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $62.66 · Expires 2030-06-03	Direct	Reported balance After 2020-09-28 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2020-09-28 · Disposition to issuer · Disposed 10,240 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of August 16, 2020, by and among Principia Biopharma Inc. (the "Issuer"), Sanofi ("Sanofi") and Kortex Acquisition Corp. ("Purchaser") (the "Merger Agreement"), on September 28, 2020, Purchaser merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Sanofi (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger, dated as of August 16, 2020, by and among Principia Biopharma Inc. (the "Issuer"), Sanofi ("Sanofi") and Kortex Acquisition Corp. ("Purchaser") (the "Merger Agreement"), on September 28, 2020, Purchaser merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Sanofi (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options.

Sio Gene Therapies Inc.

Report date July 10, 2019 · Filed July 16, 2019

Section 16 reporting ended · disclosed 2019-07-16. Current position is not established by this disclosure.

No balance rows disclosed in this filing.

Turning Point Therapeutics, Inc.

Report date August 17, 2022 · Filed August 17, 2022

Section 16 reporting ended · disclosed 2022-08-17. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.56 · Expires 2029-05-12	Direct	Reported balance After 2022-08-17 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2022-08-17 · Disposition to issuer · Disposed 30,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 2, 2022, by and among Turning Point Therapeutics, Inc. (the "Issuer"), Bristol-Myers Squibb Company ("BMS") and Rhumba Merger Sub Inc., a wholly owned subsidiary of BMS ("Purchaser"), on August 17, 2022, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of BMS (the "Merger"). F2: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $76.00 per Share over (y) the exercise price payable per Share under such option, net of any withholding taxes required to be deducted and withheld by applicable law.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $65.39 · Expires 2030-06-14	Direct	Reported balance After 2022-08-17 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2022-08-17 · Disposition to issuer · Disposed 8,500 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 2, 2022, by and among Turning Point Therapeutics, Inc. (the "Issuer"), Bristol-Myers Squibb Company ("BMS") and Rhumba Merger Sub Inc., a wholly owned subsidiary of BMS ("Purchaser"), on August 17, 2022, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of BMS (the "Merger"). F2: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $76.00 per Share over (y) the exercise price payable per Share under such option, net of any withholding taxes required to be deducted and withheld by applicable law.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $65.64 · Expires 2031-06-01	Direct	Reported balance After 2022-08-17 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2022-08-17 · Disposition to issuer · Disposed 8,500 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 2, 2022, by and among Turning Point Therapeutics, Inc. (the "Issuer"), Bristol-Myers Squibb Company ("BMS") and Rhumba Merger Sub Inc., a wholly owned subsidiary of BMS ("Purchaser"), on August 17, 2022, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of BMS (the "Merger"). F2: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $76.00 per Share over (y) the exercise price payable per Share under such option, net of any withholding taxes required to be deducted and withheld by applicable law.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 2, 2022, by and among Turning Point Therapeutics, Inc. (the "Issuer"), Bristol-Myers Squibb Company ("BMS") and Rhumba Merger Sub Inc., a wholly owned subsidiary of BMS ("Purchaser"), on August 17, 2022, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of BMS (the "Merger").

F2: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $76.00 per Share over (y) the exercise price payable per Share under such option, net of any withholding taxes required to be deducted and withheld by applicable law.

Urovant Sciences Ltd.

Report date July 10, 2019 · Filed July 16, 2019

Section 16 reporting ended · disclosed 2019-07-16. Current position is not established by this disclosure.

No balance rows disclosed in this filing.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 15, 2023 Filed Jun 17, 2023 00:05 UTC	Arcus Biosciences, Inc. RCUS · Entity 4104	GrantStock Option (Right to Buy) · Derivative	19,500	$0.00 Strike: $19.60	$0.00	Disclosure SEC source: 0001209191-23-038142 · doc4.xml · derivative · entry 2 Machado Patrick · CIK 0001311210 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,500 Underlying: Common Stock · 19,500 shares Expires 2033-06-14 F2 · derivative.exercise_date: The option will vest in full on the earlier of June 15, 2024 or the next annual meeting of stockholders of the issuer. The option will become fully vested and exercisable in the event the Company is subject to a change in control. Read SEC document
June 15, 2023 Filed Jun 17, 2023 00:05 UTC	Arcus Biosciences, Inc. RCUS · Entity 4104	GrantCommon Stock	6,800	$0.00	$0.00	Disclosure SEC source: 0001209191-23-038142 · doc4.xml · nonDerivative · entry 1 Machado Patrick · CIK 0001311210 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,900 F1 · shares: Represents the grant of restricted stock units that vest in full on the earlier of June 15, 2024 or the next annual meeting of stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control. Read SEC document
June 09, 2023 Filed Jun 12, 2023 16:28 UTC	CHIMERIX INC CMRX · Entity 80651	GrantStock Option (Right to Buy) · Derivative	60,000	$0.00 Strike: $1.39	$0.00	Disclosure SEC source: 0001209191-23-036319 · doc4.xml · derivative · entry 1 Machado Patrick · CIK 0001311210 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2033-06-08 F1 · derivative.exercise_date: The shares subject to the option vest in a series of 12 equal monthly installments from the date of grant; provided, however, that the option shall become fully vested on the date that is the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the Company's 2024 annual stockholder meeting. Read SEC document
June 09, 2023 Filed Jun 13, 2023 21:02 UTC	Adverum Biotechnologies, Inc. ADVM · Entity 71889	GrantStock Option (Right to Buy) · Derivative	12,500	$0.00 Strike: $1.56	$0.00	Disclosure SEC source: 0001209191-23-036801 · doc4.xml · derivative · entry 2 Machado Patrick · CIK 0001311210 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,500 Underlying: Common Stock · 12,500 shares Expires 2033-06-08 F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of June 9, 2024 or the 2024 annual meeting of stockholders, subject to (1) accelerated vesting upon a change of control and (2) the Reporting Person's continued service with the Issuer on the vesting date. Read SEC document
June 09, 2023 Filed Jun 13, 2023 21:02 UTC	Adverum Biotechnologies, Inc. ADVM · Entity 71889	GrantStock Option (Right to Buy) · Derivative	40,000	$0.00 Strike: $1.56	$0.00	Disclosure SEC source: 0001209191-23-036801 · doc4.xml · derivative · entry 1 Machado Patrick · CIK 0001311210 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2033-06-08 F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of June 9, 2024 or the 2024 annual meeting of stockholders, subject to (1) accelerated vesting upon a change of control and (2) the Reporting Person's continued service with the Issuer on the vesting date. Read SEC document
June 02, 2023 Filed Jun 2, 2023 21:20 UTC	Xenon Pharmaceuticals Inc. XENE · Entity 2602	GrantStock Option (Right to Buy) · Derivative	18,475	$0.00 Strike: $38.96	$0.00	Disclosure SEC source: 0000950170-23-026167 · ownership.xml · derivative · entry 1 Machado Patrick · CIK 0001311210 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,475 Underlying: Common Shares · 18,475 shares Expires 2033-06-01 F1 · derivative.exercise_date: Vesting 100% on the earlier of (i) June 1, 2024 or (ii) the day immediately preceding the day of the following year's annual meeting. Read SEC document
May 09, 2023 Filed May 12, 2023 01:09 UTC	ACELYRIN, Inc. SLRN · Entity 79310	OtherDirector Stock Option (right to buy) · Derivative	23,243	$0.00 Strike: $18.00	$0.00	Disclosure SEC source: 0001209191-23-028880 · doc4.xml · derivative · entry 8 Machado Patrick · CIK 0001311210 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,243 Underlying: Common Stock · 23,243 shares Expires 2033-05-03 F1 · kind: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock. F5 · derivative.exercise_date: 1/36 of the shares subject to the option vest on June 4, 2023, and 1/36 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service. F1 · derivative.underlying: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock. Read SEC document
May 09, 2023 Filed May 12, 2023 01:09 UTC	ACELYRIN, Inc. SLRN · Entity 79310	OtherDirector Stock Option (right to buy) · Derivative	23,243	$0.00 Strike: $18.00	$0.00	Disclosure SEC source: 0001209191-23-028880 · doc4.xml · derivative · entry 7 Machado Patrick · CIK 0001311210 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 23,243 shares Expires 2033-05-03 F1 · kind: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock. F5 · derivative.exercise_date: 1/36 of the shares subject to the option vest on June 4, 2023, and 1/36 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service. F1 · derivative.underlying: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock. Read SEC document
May 09, 2023 Filed May 12, 2023 01:09 UTC	ACELYRIN, Inc. SLRN · Entity 79310	OtherDirector Stock Option (right to buy) · Derivative	28,675	$0.00 Strike: $5.88	$0.00	Disclosure SEC source: 0001209191-23-028880 · doc4.xml · derivative · entry 6 Machado Patrick · CIK 0001311210 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,675 Underlying: Common Stock · 28,675 shares Expires 2032-11-20 F1 · kind: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock. F4 · derivative.exercise_date: 1/48 of the shares subject to the option vested on December 17, 2022 and 1/48 of the shares subject to the option vests in equal monthly installments thereafter, subject to the Reporting Person's continued service. F1 · derivative.underlying: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock. Read SEC document
May 09, 2023 Filed May 12, 2023 01:09 UTC	ACELYRIN, Inc. SLRN · Entity 79310	OtherDirector Stock Option (right to buy) · Derivative	28,675	$0.00 Strike: $5.88	$0.00	Disclosure SEC source: 0001209191-23-028880 · doc4.xml · derivative · entry 5 Machado Patrick · CIK 0001311210 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 28,675 shares Expires 2032-11-20 F1 · kind: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock. F4 · derivative.exercise_date: 1/48 of the shares subject to the option vested on December 17, 2022 and 1/48 of the shares subject to the option vests in equal monthly installments thereafter, subject to the Reporting Person's continued service. F1 · derivative.underlying: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock. Read SEC document
May 09, 2023 Filed May 12, 2023 01:09 UTC	ACELYRIN, Inc. SLRN · Entity 79310	OtherDirector Stock Option (right to buy) · Derivative	86,206	$0.00 Strike: $5.88	$0.00	Disclosure SEC source: 0001209191-23-028880 · doc4.xml · derivative · entry 4 Machado Patrick · CIK 0001311210 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,206 Underlying: Common Stock · 86,206 shares Expires 2032-11-20 F1 · kind: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock. F3 · derivative.exercise_date: 1/48 of the shares subject to the option vested on November 1, 2022 and 1/48 of the shares subject to the option vests in equal monthly installments thereafter, subject to the Reporting Person's continued service. Read SEC document
May 09, 2023 Filed May 12, 2023 01:09 UTC	ACELYRIN, Inc. SLRN · Entity 79310	OtherDirector Stock Option (right to buy) · Derivative	86,206	$0.00 Strike: $5.88	$0.00	Disclosure SEC source: 0001209191-23-028880 · doc4.xml · derivative · entry 3 Machado Patrick · CIK 0001311210 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 86,206 shares Expires 2032-11-20 F1 · kind: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock. F3 · derivative.exercise_date: 1/48 of the shares subject to the option vested on November 1, 2022 and 1/48 of the shares subject to the option vests in equal monthly installments thereafter, subject to the Reporting Person's continued service. Read SEC document
May 09, 2023 Filed May 12, 2023 01:09 UTC	ACELYRIN, Inc. SLRN · Entity 79310	OtherDirector Stock Option (right to buy) · Derivative	40,567	$0.00 Strike: $0.77	$0.00	Disclosure SEC source: 0001209191-23-028880 · doc4.xml · derivative · entry 2 Machado Patrick · CIK 0001311210 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,567 Underlying: Common Stock · 40,567 shares Expires 2031-07-25 F1 · kind: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock. F2 · derivative.exercise_date: 1/48 of the shares subject to the option vested on May 19, 2021 and 1/48 of the shares subject to the option vests in equal monthly installments thereafter, subject to the Reporting Person's continued service. Read SEC document
May 09, 2023 Filed May 12, 2023 01:09 UTC	ACELYRIN, Inc. SLRN · Entity 79310	OtherDirector Stock Option (right to buy) · Derivative	40,567	$0.00 Strike: $0.77	$0.00	Disclosure SEC source: 0001209191-23-028880 · doc4.xml · derivative · entry 1 Machado Patrick · CIK 0001311210 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 40,567 shares Expires 2031-07-25 F1 · kind: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock. F2 · derivative.exercise_date: 1/48 of the shares subject to the option vested on May 19, 2021 and 1/48 of the shares subject to the option vests in equal monthly installments thereafter, subject to the Reporting Person's continued service. Read SEC document
May 04, 2023 Filed May 5, 2023 00:16 UTC	ACELYRIN, Inc. SLRN · Entity 79310	GrantDirector Stock Option (right to buy) · Derivative	23,243	$0.00 Strike: $18.00	$0.00	Disclosure SEC source: 0001209191-23-027534 · doc4.xml · derivative · entry 1 Machado Patrick · CIK 0001311210 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,243 Underlying: Class A Common · 23,243 shares Expires 2033-05-03 F1 · derivative.exercise_date: 1/36 of the shares subject to the option vest on June 4, 2023, and 1/36 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service. F2 · derivative.underlying: Each share of Class A Common Stock shall be reclassified into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock. Read SEC document
August 17, 2022 Filed Aug 17, 2022 20:41 UTC	Turning Point Therapeutics, Inc. TPTX · Entity 124461	Disposition to issuerStock Option (right to buy) · Derivative	8,500	Not disclosed Strike: $65.64	Not disclosed	Disclosure SEC source: 0001209191-22-046286 · doc4.xml · derivative · entry 3 Machado Patrick · CIK 0001311210 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,500 shares Expires 2031-06-01 F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 2, 2022, by and among Turning Point Therapeutics, Inc. (the "Issuer"), Bristol-Myers Squibb Company ("BMS") and Rhumba Merger Sub Inc., a wholly owned subsidiary of BMS ("Purchaser"), on August 17, 2022, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of BMS (the "Merger"). F2 · price: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $76.00 per Share over (y) the exercise price payable per Share under such option, net of any withholding taxes required to be deducted and withheld by applicable law. F2 · derivative.exercise_date: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $76.00 per Share over (y) the exercise price payable per Share under such option, net of any withholding taxes required to be deducted and withheld by applicable law. Read SEC document
August 17, 2022 Filed Aug 17, 2022 20:41 UTC	Turning Point Therapeutics, Inc. TPTX · Entity 124461	Disposition to issuerStock Option (right to buy) · Derivative	8,500	Not disclosed Strike: $65.39	Not disclosed	Disclosure SEC source: 0001209191-22-046286 · doc4.xml · derivative · entry 2 Machado Patrick · CIK 0001311210 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,500 shares Expires 2030-06-14 F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 2, 2022, by and among Turning Point Therapeutics, Inc. (the "Issuer"), Bristol-Myers Squibb Company ("BMS") and Rhumba Merger Sub Inc., a wholly owned subsidiary of BMS ("Purchaser"), on August 17, 2022, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of BMS (the "Merger"). F2 · price: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $76.00 per Share over (y) the exercise price payable per Share under such option, net of any withholding taxes required to be deducted and withheld by applicable law. F2 · derivative.exercise_date: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $76.00 per Share over (y) the exercise price payable per Share under such option, net of any withholding taxes required to be deducted and withheld by applicable law. Read SEC document
August 17, 2022 Filed Aug 17, 2022 20:41 UTC	Turning Point Therapeutics, Inc. TPTX · Entity 124461	Disposition to issuerStock Option (right to buy) · Derivative	30,000	Not disclosed Strike: $29.56	Not disclosed	Disclosure SEC source: 0001209191-22-046286 · doc4.xml · derivative · entry 1 Machado Patrick · CIK 0001311210 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2029-05-12 F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 2, 2022, by and among Turning Point Therapeutics, Inc. (the "Issuer"), Bristol-Myers Squibb Company ("BMS") and Rhumba Merger Sub Inc., a wholly owned subsidiary of BMS ("Purchaser"), on August 17, 2022, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of BMS (the "Merger"). F2 · price: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $76.00 per Share over (y) the exercise price payable per Share under such option, net of any withholding taxes required to be deducted and withheld by applicable law. F2 · derivative.exercise_date: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $76.00 per Share over (y) the exercise price payable per Share under such option, net of any withholding taxes required to be deducted and withheld by applicable law. Read SEC document
June 28, 2022 Filed Jun 29, 2022 21:34 UTC	Xenon Pharmaceuticals Inc. XENE · Entity 2602	GrantStock Option (Right to Buy) · Derivative	18,000	$0.00 Strike: $30.11	$0.00	Disclosure SEC source: 0001209191-22-039831 · doc4.xml · derivative · entry 1 Machado Patrick · CIK 0001311210 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Shares · 18,000 shares Expires 2032-06-27 F1 · derivative.exercise_date: 100% of the common shares subject to the option will vest on the earlier of (i) the first anniversary of grant date and (ii) the day immediately preceding the day of the Issuer's next annual general meeting of shareholders. Read SEC document
June 23, 2022 Filed Jun 24, 2022 11:10 UTC	CHIMERIX INC CMRX · Entity 80651	GrantStock Option (Right to Buy) · Derivative	50,000	$0.00 Strike: $1.82	$0.00	Disclosure SEC source: 0001209191-22-039117 · doc4.xml · derivative · entry 1 Machado Patrick · CIK 0001311210 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2032-06-22 F1 · derivative.exercise_date: The shares subject to the option vest in a series of 12 equal monthly installments from the date of grant; provided, however, that the option shall become fully vested on the date that is the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the Company's 2023 annual stockholder meeting. Read SEC document
June 14, 2022 Filed Jun 16, 2022 20:26 UTC	Arcus Biosciences, Inc. RCUS · Entity 4104	GrantStock Option (Right to Buy) · Derivative	16,800	$0.00 Strike: $20.62	$0.00	Disclosure SEC source: 0001209191-22-037417 · doc4.xml · derivative · entry 2 Machado Patrick · CIK 0001311210 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,800 Underlying: Common Stock · 16,800 shares Expires 2032-06-13 F3 · derivative.exercise_date: The option will vest in full on the earlier of June 14, 2023 or the next annual meeting of stockholders of the issuer. The option will become fully vested and exercisable in the event the Company is subject to a change in control. Read SEC document
June 14, 2022 Filed Jun 16, 2022 20:26 UTC	Arcus Biosciences, Inc. RCUS · Entity 4104	GrantCommon Stock	4,100	$0.00	$0.00	Disclosure SEC source: 0001209191-22-037417 · doc4.xml · nonDerivative · entry 1 Machado Patrick · CIK 0001311210 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,100 F1 · shares: Represents the grant of restricted stock units that vest in full on the earlier of June 14, 2023 or the next annual meeting of stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control. F2 · balance_after: Includes 3,000 shares of restricted stock units (previously reported) that vested on June 3, 2022. Read SEC document
June 10, 2022 Filed Jun 14, 2022 20:19 UTC	Adverum Biotechnologies, Inc. ADVM · Entity 71889	GrantStock Option (Right to Buy) · Derivative	12,500	$0.00 Strike: $0.99	$0.00	Disclosure SEC source: 0001209191-22-036675 · doc4.xml · derivative · entry 2 Machado Patrick · CIK 0001311210 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2032-06-09 F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of June 10, 2023 or the 2023 annual meeting of stockholders, subject to (1) accelerated vesting upon a change of control and (2) the Reporting Person's continued service with the Issuer on the vesting date. Read SEC document
June 10, 2022 Filed Jun 14, 2022 20:19 UTC	Adverum Biotechnologies, Inc. ADVM · Entity 71889	GrantStock Option (Right to Buy) · Derivative	40,000	$0.00 Strike: $0.99	$0.00	Disclosure SEC source: 0001209191-22-036675 · doc4.xml · derivative · entry 1 Machado Patrick · CIK 0001311210 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2032-06-09 F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of June 10, 2023 or the 2023 annual meeting of stockholders, subject to (1) accelerated vesting upon a change of control and (2) the Reporting Person's continued service with the Issuer on the vesting date. Read SEC document
June 23, 2021 Filed Jun 25, 2021 17:24 UTC	CHIMERIX INC CMRX · Entity 80651	GrantStock Option (Right to Buy) · Derivative	35,000	$0.00 Strike: $7.84	$0.00	Disclosure SEC source: 0001209191-21-043350 · doc4.xml · derivative · entry 1 Machado Patrick · CIK 0001311210 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2031-06-22 F1 · derivative.exercise_date: The shares subject to the option vest in a series of 12 equal monthly installments from the date of grant; provided, however, that the option shall become fully vested on the date that is the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the Company's 2022 annual stockholder meeting. Read SEC document
June 03, 2021 Filed Jun 4, 2021 01:09 UTC	Xenon Pharmaceuticals Inc. XENE · Entity 2602	GrantStock Option (Right to Buy) · Derivative	10,000	$0.00 Strike: $18.56	$0.00	Disclosure SEC source: 0001209191-21-038070 · doc4.xml · derivative · entry 1 Machado Patrick · CIK 0001311210 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Shares · 10,000 shares Expires 2031-06-02 F1 · derivative.exercise_date: One-third of the total shares subject to the Option shall vest on the one year anniversary of the grant date, one-third of the total shares subject to the Option shall vest on the two year anniversary of the grant date, one-third of the total shares subject to the Option shall vest on the three year anniversary of the grant date. Read SEC document
June 03, 2021 Filed Jun 7, 2021 20:40 UTC	Arcus Biosciences, Inc. RCUS · Entity 4104	GrantStock Option (Right to Buy) · Derivative	14,100	$0.00 Strike: $24.79	$0.00	Disclosure SEC source: 0001209191-21-038628 · doc4.xml · derivative · entry 2 Machado Patrick · CIK 0001311210 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,100 Underlying: Common Stock · 14,100 shares Expires 2031-06-02 F3 · derivative.exercise_date: The option will vest in full on the earlier of (i) 12 months following the date of grant or (ii) the date of the next annual stockholder meeting following the grant. The option becomes fully vested and exercisable in the event the Company is subject to a change in control. Read SEC document
June 03, 2021 Filed Jun 7, 2021 20:40 UTC	Arcus Biosciences, Inc. RCUS · Entity 4104	GrantCommon Stock	3,000	$0.00	$0.00	Disclosure SEC source: 0001209191-21-038628 · doc4.xml · nonDerivative · entry 1 Machado Patrick · CIK 0001311210 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 F1 · shares: Represents the grant of restricted stock units that vest 100% on the earlier of June 3, 2022 or the next annual meeting of the stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control. F2 · balance_after: Includes 3,000 shares of restricted stock units (previously reported) that vested on June 3, 2021. Read SEC document
June 02, 2021 Filed Jun 4, 2021 21:41 UTC	Turning Point Therapeutics, Inc. TPTX · Entity 124461	GrantStock Option (right to buy) · Derivative	8,500	$0.00 Strike: $65.64	$0.00	Disclosure SEC source: 0001209191-21-038334 · doc4.xml · derivative · entry 1 Machado Patrick · CIK 0001311210 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,500 Underlying: Common Stock · 8,500 shares Expires 2031-06-01 F1 · derivative.exercise_date: The shares vest on the one-year anniversary of the date of grant. Read SEC document
May 12, 2021 Filed May 15, 2021 00:01 UTC	Adverum Biotechnologies, Inc. ADVM · Entity 71889	GrantStock Option (Right to Buy) · Derivative	12,500	$0.00 Strike: $3.70	$0.00	Disclosure SEC source: 0001209191-21-032953 · doc4.xml · derivative · entry 2 Machado Patrick · CIK 0001311210 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2031-05-11 F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of May 12, 2022 or the 2022 annual meeting of stockholders, subject to (1) accelerated vesting upon a change of control and (2) the Reporting Person's continued service with the Issuer on the vesting date. Read SEC document
May 12, 2021 Filed May 15, 2021 00:01 UTC	Adverum Biotechnologies, Inc. ADVM · Entity 71889	GrantStock Option (Right to Buy) · Derivative	40,000	$0.00 Strike: $3.70	$0.00	Disclosure SEC source: 0001209191-21-032953 · doc4.xml · derivative · entry 1 Machado Patrick · CIK 0001311210 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2031-05-11 F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of May 12, 2022 or the 2022 annual meeting of stockholders, subject to (1) accelerated vesting upon a change of control and (2) the Reporting Person's continued service with the Issuer on the vesting date. Read SEC document
March 24, 2021 Filed Mar 24, 2021 23:46 UTC	Adverum Biotechnologies, Inc. ADVM · Entity 71889	PurchaseCommon Stock	10,000	$9.92	$99,196.00	Disclosure SEC source: 0001209191-21-022933 · doc4.xml · nonDerivative · entry 1 Machado Patrick · CIK 0001311210 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,182 F1 · price: Price reported is a weighted-average purchase price. The shares were purchased at prices ranging from $9.76 to $10.045. The Reporting Person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares purchased at each separate price. Read SEC document
January 15, 2021 Filed Jan 20, 2021 01:33 UTC	Adverum Biotechnologies, Inc. ADVM · Entity 71889	PurchaseCommon Stock	10,000	$11.52	$115,174.00	Disclosure SEC source: 0001209191-21-004143 · doc4.xml · nonDerivative · entry 1 Machado Patrick · CIK 0001311210 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,182 F1 · price: Price reported is a weighted-average purchase price. The shares were purchased at prices ranging from $11.495 to $11.52. The Reporting Person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares purchased at each separate price. Read SEC document
November 05, 2020 Filed Nov 6, 2020 00:14 UTC	Xenon Pharmaceuticals Inc. XENE · Entity 2602	GrantStock Option (Right to Buy) · Derivative	20,000	$0.00 Strike: $11.85	$0.00	Disclosure SEC source: 0001209191-20-057208 · doc4.xml · derivative · entry 1 Machado Patrick · CIK 0001311210 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Shares · 20,000 shares Expires 2030-11-04 F1 · derivative.exercise_date: One-third of the total shares subject to the Option shall vest on the one year anniversary of the grant date, one-third of the total shares subject to the Option shall vest on the two year anniversary of the grant date, and one-third of the total shares subject to the Option shall vest on the three year anniversary of the grant date. Read SEC document
September 28, 2020 Filed Sep 28, 2020 21:28 UTC	Principia Biopharma Inc. PRNB · Entity 146423	Disposition to issuerDirector Stock Option (right to buy) · Derivative	10,240	Not disclosed Strike: $62.66	Not disclosed	Disclosure SEC source: 0001209191-20-052235 · doc4.xml · derivative · entry 3 Machado Patrick · CIK 0001311210 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,240 shares Expires 2030-06-03 F1 · kind: Pursuant to the Agreement and Plan of Merger, dated as of August 16, 2020, by and among Principia Biopharma Inc. (the "Issuer"), Sanofi ("Sanofi") and Kortex Acquisition Corp. ("Purchaser") (the "Merger Agreement"), on September 28, 2020, Purchaser merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Sanofi (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options. F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of August 16, 2020, by and among Principia Biopharma Inc. (the "Issuer"), Sanofi ("Sanofi") and Kortex Acquisition Corp. ("Purchaser") (the "Merger Agreement"), on September 28, 2020, Purchaser merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Sanofi (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options. F1 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated as of August 16, 2020, by and among Principia Biopharma Inc. (the "Issuer"), Sanofi ("Sanofi") and Kortex Acquisition Corp. ("Purchaser") (the "Merger Agreement"), on September 28, 2020, Purchaser merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Sanofi (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options. Read SEC document
September 28, 2020 Filed Sep 28, 2020 21:28 UTC	Principia Biopharma Inc. PRNB · Entity 146423	Disposition to issuerDirector Stock Option (right to buy) · Derivative	10,240	Not disclosed Strike: $31.77	Not disclosed	Disclosure SEC source: 0001209191-20-052235 · doc4.xml · derivative · entry 2 Machado Patrick · CIK 0001311210 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,240 shares Expires 2029-06-10 F1 · kind: Pursuant to the Agreement and Plan of Merger, dated as of August 16, 2020, by and among Principia Biopharma Inc. (the "Issuer"), Sanofi ("Sanofi") and Kortex Acquisition Corp. ("Purchaser") (the "Merger Agreement"), on September 28, 2020, Purchaser merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Sanofi (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options. F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of August 16, 2020, by and among Principia Biopharma Inc. (the "Issuer"), Sanofi ("Sanofi") and Kortex Acquisition Corp. ("Purchaser") (the "Merger Agreement"), on September 28, 2020, Purchaser merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Sanofi (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options. F1 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated as of August 16, 2020, by and among Principia Biopharma Inc. (the "Issuer"), Sanofi ("Sanofi") and Kortex Acquisition Corp. ("Purchaser") (the "Merger Agreement"), on September 28, 2020, Purchaser merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Sanofi (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options. Read SEC document
September 28, 2020 Filed Sep 28, 2020 21:28 UTC	Principia Biopharma Inc. PRNB · Entity 146423	Disposition to issuerDirector Stock Option (right to buy) · Derivative	20,475	Not disclosed Strike: $31.77	Not disclosed	Disclosure SEC source: 0001209191-20-052235 · doc4.xml · derivative · entry 1 Machado Patrick · CIK 0001311210 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,475 shares Expires 2029-06-10 F1 · kind: Pursuant to the Agreement and Plan of Merger, dated as of August 16, 2020, by and among Principia Biopharma Inc. (the "Issuer"), Sanofi ("Sanofi") and Kortex Acquisition Corp. ("Purchaser") (the "Merger Agreement"), on September 28, 2020, Purchaser merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Sanofi (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options. F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of August 16, 2020, by and among Principia Biopharma Inc. (the "Issuer"), Sanofi ("Sanofi") and Kortex Acquisition Corp. ("Purchaser") (the "Merger Agreement"), on September 28, 2020, Purchaser merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Sanofi (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options. F1 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated as of August 16, 2020, by and among Principia Biopharma Inc. (the "Issuer"), Sanofi ("Sanofi") and Kortex Acquisition Corp. ("Purchaser") (the "Merger Agreement"), on September 28, 2020, Purchaser merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Sanofi (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options. Read SEC document
June 23, 2020 Filed Jun 25, 2020 21:46 UTC	Adverum Biotechnologies, Inc. ADVM · Entity 71889	GrantStock Option (Right to Buy) · Derivative	30,000	$0.00 Strike: $25.64	$0.00	Disclosure SEC source: 0001209191-20-038962 · doc4.xml · derivative · entry 1 Machado Patrick · CIK 0001311210 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2030-06-22 F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of June 23, 2021 or the 2021 annual meeting of stockholders, subject to (1) accelerated vesting upon a change of control and (2) the Reporting Person's continued service with the Issuer on the vesting date. Read SEC document
June 15, 2020 Filed Jun 17, 2020 23:06 UTC	Turning Point Therapeutics, Inc. TPTX · Entity 124461	GrantStock Option (right to buy) · Derivative	8,500	$0.00 Strike: $65.39	$0.00	Disclosure SEC source: 0001209191-20-037415 · doc4.xml · derivative · entry 1 Machado Patrick · CIK 0001311210 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,500 Underlying: Common Stock · 8,500 shares Expires 2030-06-14 F1 · derivative.exercise_date: The shares vest on the one-year anniversary of the date of grant. Read SEC document
June 11, 2020 Filed Jun 15, 2020 12:43 UTC	CHIMERIX INC CMRX · Entity 80651	GrantStock Option (Right to Buy) · Derivative	35,000	$0.00 Strike: $2.85	$0.00	Disclosure SEC source: 0001209191-20-036526 · doc4.xml · derivative · entry 1 Machado Patrick · CIK 0001311210 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2030-06-10 F1 · derivative.exercise_date: The shares subject to the option vest in a series of 12 equal monthly installments from the date of grant; provided, however, that the option shall become fully vested on the date that is the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the Company's 2020 annual stockholder meeting. Read SEC document
June 04, 2020 Filed Jun 8, 2020 20:32 UTC	Arcus Biosciences, Inc. RCUS · Entity 4104	GrantStock Option (Right to Buy) · Derivative	14,000	$0.00 Strike: $30.05	$0.00	Disclosure SEC source: 0001209191-20-034986 · doc4.xml · derivative · entry 2 Machado Patrick · CIK 0001311210 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires 2030-06-03 F2 · derivative.exercise_date: The option will vest in full on the earlier of (i) 12 months following the date of grant or (ii) the date of the next annual stockholder meeting following the grant. The option becomes fully vested and exercisable in the event the Company is subject to a change in control. Read SEC document
June 04, 2020 Filed Jun 8, 2020 20:32 UTC	Arcus Biosciences, Inc. RCUS · Entity 4104	GrantCommon Stock	3,000	$0.00	$0.00	Disclosure SEC source: 0001209191-20-034986 · doc4.xml · nonDerivative · entry 1 Machado Patrick · CIK 0001311210 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 F1 · shares: Represents the grant of restricted stock units that vest 100% on the earlier of June 4, 2021 or the next annual meeting of the stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control Read SEC document
June 04, 2020 Filed Jun 9, 2020 00:10 UTC	Principia Biopharma Inc. PRNB · Entity 146423	GrantDirector Stock Option (right to buy) · Derivative	10,240	$0.00 Strike: $62.66	$0.00	Disclosure SEC source: 0001209191-20-035143 · doc4.xml · derivative · entry 1 Machado Patrick · CIK 0001311210 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,240 Underlying: Common Stock · 10,240 shares Expires 2030-06-03 F1 · derivative.exercise_date: The stock option vests in equal monthly installments over a one year period such that the option is fully vested on the first anniversary of the date of grant, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document
January 01, 2020 Filed Jan 3, 2020 21:34 UTC	Adverum Biotechnologies, Inc. ADVM · Entity 71889	GrantStock Option (Right to Buy) · Derivative	15,000	$0.00 Strike: $11.52	$0.00	Disclosure SEC source: 0001209191-20-001014 · doc4.xml · derivative · entry 1 Machado Patrick · CIK 0001311210 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2029-12-31 F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier to occur of 18 months following January 1, 2020 or the 2021 annual meeting of stockholders. Read SEC document
December 10, 2019 Filed Dec 12, 2019 17:18 UTC	Arcus Biosciences, Inc. RCUS · Entity 4104	GrantStock Option (right to buy) · Derivative	50,000	$0.00 Strike: $8.55	$0.00	Disclosure SEC source: 0001209191-19-060168 · doc4.xml · derivative · entry 1 Machado Patrick · CIK 0001311210 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2029-12-09 F1 · derivative.exercise_date: The option is exercisable in 36 equal monthly installments after December 10, 2019, subject to the Reporting Person's continued service to the Company. Read SEC document
July 31, 2019 Filed Aug 2, 2019 20:27 UTC	Adverum Biotechnologies, Inc. ADVM · Entity 71889	GrantStock Option (Right to Buy) · Derivative	45,000	$0.00 Strike: $13.41	$0.00	Disclosure SEC source: 0001209191-19-044260 · doc4.xml · derivative · entry 1 Machado Patrick · CIK 0001311210 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2029-07-30 F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of (a) the 2020 annual meeting of stockholders and (b) July 31, 2020. Read SEC document
June 20, 2019 Filed Jun 24, 2019 14:37 UTC	CHIMERIX INC CMRX · Entity 80651	GrantStock Option (Right to Buy) · Derivative	21,000	$0.00 Strike: $3.37	$0.00	Disclosure SEC source: 0001209191-19-038725 · doc4.xml · derivative · entry 1 Machado Patrick · CIK 0001311210 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 Underlying: Common Stock · 21,000 shares Expires 2029-06-19 F1 · derivative.exercise_date: The shares subject to the option vest in a series of 12 equal monthly installments from the date of grant; provided, however, that the option shall become fully vested on the date that is the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the Company's 2020 annual stockholder meeting. Read SEC document
June 19, 2019 Filed Jun 19, 2019 22:30 UTC	Urovant Sciences Ltd. UROV · Entity 140739	PurchaseCommon Shares, par value $0.000037453 per share	4,957	$8.17	$40,495.22	Disclosure SEC source: 0001104659-19-036422 · a4.xml · nonDerivative · entry 3 Machado Patrick · CIK 0001311210 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 22,860,013 F1 · shares: The transaction was a series of open market purchases made by Roivant Sciences Ltd. ("Roivant") under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and in accordance with the safe harbor of Rule 10b-18 under the Exchange Act. The purchases were made by Roivant and not by the reporting person. See footnotes 3 and 4 for information on the reporting person's ownership via Roivant of the purchased Common Shares. F6 · price: The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $8.00 to $8.27, inclusive. The reporting person undertakes to provide to Urovant, any security holder of Urovant, or the staff of the SEC, upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (6) to this Form 4. F3 · ownership.nature: These Common Shares are directly beneficially owned by Roivant and indirectly beneficially owned by the reporting person. Pursuant to Roivant's internal governance documents, following the appointment to Roivant's board of directors of one or more directors meeting certain independence criteria (each an "Independent Director" and collectively the "Independent Directors"), dispositions of the Common Shares require the approval of a majority of Roivant's board of directors, including (i) at least two Independent Directors, or, (ii) if there is only one independent director, that sole Independent Director. The reporting person was appointed as an Independent Director of Roivant effective October 18, 2016. F4 · ownership.nature: As the approval of the reporting person as an Independent Director, and, to the extent one other Independent Director is serving, that other Independent Director, is needed for Roivant to dispose of the Common Shares, the reporting person may be deemed to have dispositive power over, and to be an indirect beneficial owner of, the Common Shares directly beneficially owned by Roivant. The reporting person disclaims beneficial ownership of the shares owned by Roivant, except to the extent of his respective pecuniary interest therein. Additionally, this filing shall not be deemed an admission that the reporting person and any other Independent Director constitute a "group" for purposes of Section 13(d) or Section 13(g) of the Securities Exchange Act of 1934, as amended. Read SEC document
June 18, 2019 Filed Jun 19, 2019 22:30 UTC	Urovant Sciences Ltd. UROV · Entity 140739	PurchaseCommon Shares, par value $0.000037453 per share	6,706	$8.21	$55,060.95	Disclosure SEC source: 0001104659-19-036422 · a4.xml · nonDerivative · entry 2 Machado Patrick · CIK 0001311210 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 22,855,056 F1 · shares: The transaction was a series of open market purchases made by Roivant Sciences Ltd. ("Roivant") under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and in accordance with the safe harbor of Rule 10b-18 under the Exchange Act. The purchases were made by Roivant and not by the reporting person. See footnotes 3 and 4 for information on the reporting person's ownership via Roivant of the purchased Common Shares. F5 · price: The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $8.09 to $8.29, inclusive. The reporting person undertakes to provide to Urovant, any security holder of Urovant, or the staff of the SEC, upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (5) to this Form 4. F3 · ownership.nature: These Common Shares are directly beneficially owned by Roivant and indirectly beneficially owned by the reporting person. Pursuant to Roivant's internal governance documents, following the appointment to Roivant's board of directors of one or more directors meeting certain independence criteria (each an "Independent Director" and collectively the "Independent Directors"), dispositions of the Common Shares require the approval of a majority of Roivant's board of directors, including (i) at least two Independent Directors, or, (ii) if there is only one independent director, that sole Independent Director. The reporting person was appointed as an Independent Director of Roivant effective October 18, 2016. F4 · ownership.nature: As the approval of the reporting person as an Independent Director, and, to the extent one other Independent Director is serving, that other Independent Director, is needed for Roivant to dispose of the Common Shares, the reporting person may be deemed to have dispositive power over, and to be an indirect beneficial owner of, the Common Shares directly beneficially owned by Roivant. The reporting person disclaims beneficial ownership of the shares owned by Roivant, except to the extent of his respective pecuniary interest therein. Additionally, this filing shall not be deemed an admission that the reporting person and any other Independent Director constitute a "group" for purposes of Section 13(d) or Section 13(g) of the Securities Exchange Act of 1934, as amended. Read SEC document
June 17, 2019 Filed Jun 19, 2019 22:30 UTC	Urovant Sciences Ltd. UROV · Entity 140739	PurchaseCommon Shares, par value $0.000037453 per share	6,541	$8.53	$55,824.82	Disclosure SEC source: 0001104659-19-036422 · a4.xml · nonDerivative · entry 1 Machado Patrick · CIK 0001311210 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 22,848,350 F1 · shares: The transaction was a series of open market purchases made by Roivant Sciences Ltd. ("Roivant") under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and in accordance with the safe harbor of Rule 10b-18 under the Exchange Act. The purchases were made by Roivant and not by the reporting person. See footnotes 3 and 4 for information on the reporting person's ownership via Roivant of the purchased Common Shares. F2 · price: The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $8.11 to $8.70, inclusive. The reporting person undertakes to provide to Urovant Sciences Ltd. ("Urovant"), any security holder of Urovant, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4. F3 · ownership.nature: These Common Shares are directly beneficially owned by Roivant and indirectly beneficially owned by the reporting person. Pursuant to Roivant's internal governance documents, following the appointment to Roivant's board of directors of one or more directors meeting certain independence criteria (each an "Independent Director" and collectively the "Independent Directors"), dispositions of the Common Shares require the approval of a majority of Roivant's board of directors, including (i) at least two Independent Directors, or, (ii) if there is only one independent director, that sole Independent Director. The reporting person was appointed as an Independent Director of Roivant effective October 18, 2016. F4 · ownership.nature: As the approval of the reporting person as an Independent Director, and, to the extent one other Independent Director is serving, that other Independent Director, is needed for Roivant to dispose of the Common Shares, the reporting person may be deemed to have dispositive power over, and to be an indirect beneficial owner of, the Common Shares directly beneficially owned by Roivant. The reporting person disclaims beneficial ownership of the shares owned by Roivant, except to the extent of his respective pecuniary interest therein. Additionally, this filing shall not be deemed an admission that the reporting person and any other Independent Director constitute a "group" for purposes of Section 13(d) or Section 13(g) of the Securities Exchange Act of 1934, as amended. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.